Log in to post a reply
Jun 11, 2017 06:55PM
Jun 11, 2017 07:03PM
Re: "In the past few years, the scale has changed from 1-100, to 1-50."
I don't agree with that statement, and would recommend that you check the content of your Oncotype report (see the printed matter above the first graph) and discuss it with your Medical Oncologist.
Meanwhile, Genomic Health (the sole commercial provider of the test) has done a complete overhaul of its website in the last month or so, so it should be up to date regarding the scale. The site clearly indicates that there has been no change in the scale: Recurrence Scores continue to be from 0 to 100 as explained here:
>>> Genomic Health: http://www.oncotypeiq.com/en-US/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/interpreting-the-results
>>> "Genomic Health makes understanding Oncotype DX Breast Recurrence Score test results as easy as possible. A detailed Breast Recurrence Score report is generated for each patient. The report contains the Recurrence Score result—a number between 0-100—that assesses the 10-year risk of distant recurrence  in node-negative patients, 5-year distant recurrence or mortality in node-positive patients and the likelihood that chemotherapy will benefit your patient.[2, 4]"
You can download a sample node-negative (N0) report (copyright 2016) on this page here:
Although the first graph in the sample node-negative report only illustrates the relationship between Recurrence Risk and Recurrence Score for scores up to 50, the Recurrence Score can still be any value from 0 to 100. In fact, on page 1 of the sample report, above the first graph, in the box entitled "Recurrence Score Result" it is expressly stated (screen shot):
Stage IA IDC, 9/2013 BMX. Right: IDC (1.5 mm, grade 2) with DCIS (5+ cm), 0/4 nodes, pN0. Left: DCIS (5+ cm), 0/1 node, pN0(i+).